Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694723 | 1.00 | KIF11 (0.60) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL29832496 | 0.83 | KIF11 (0.50) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL13060384 | 0.82 | KIF11 (0.62) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL462675 | 0.82 | KIF11 (0.62) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL8208883 | 0.81 | TSHR (0.48) | KIF11 | |
| SCHEMBL8592606 | 0.81 | KIF11 (0.60) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL17964412 | 0.81 | KIF11 (0.70) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL5838167 | 0.81 | KIF11 (0.60) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL15212173 | 0.79 | KIF11 (0.68) | KIF11KCNH2CA4LMNAHTT | |
| SCHEMBL22150730 | 0.79 | KIF11 (0.71) | KIF11KCNH2CA4LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | ZHEJIANG PEPTITES BIOTECH CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20240116980-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | ZHEJIANG PEPTITES BIOTECH CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-115698212-A | Binder and preparation method thereof, secondary battery, battery module, battery pack and electric device | 宁德时代新能源科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20210277051-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | ZHEJIANG PEPTITES BIOTECH CO., LTD (CN) | 2021-09-09 | — | — | US | disclosed |
| US-20190264203-A1 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10131907-B2 | Glycoconjugates of RNA interference agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20150065558-A1 | Glycoconjugates of RNA Interference Agents | BANK OF AMERICA, N.A. | 2015-03-05 | — | — | US | disclosed |
| US-8877917-B2 | Glycoconjugates of RNA interference agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20090203135-A1 | Glycoconjugates of RNA Interference Agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008131419-A2 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277051-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | SEM1, REN, SETDB1 | KIF11 2009/4885KCNH2 3525/4885CA4 744/4885 |
| US-20150065558-A1 | Glycoconjugates of RNA Interference Agents | RNASE1, B3GAT3, UGCG | KIF11 2760/4885KCNH2 4807/4885CA4 3604/4885 |
| US-10131907-B2 | Glycoconjugates of RNA interference agents | RNASE1, B3GAT3, UGCG | KIF11 2760/4885KCNH2 4807/4885CA4 3604/4885 |
| US-20240116980-A1 | COMPOUND OR SALT THEREOF AND PREPARATION METHOD AND APPLICATION OF SAME | SEM1, REN, SETDB1 | KIF11 2009/4885KCNH2 3525/4885CA4 744/4885 |
| US-20190264203-A1 | GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS | RNASE1, B3GAT3, UGCG | KIF11 2760/4885KCNH2 4807/4885CA4 3604/4885 |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | SEM1, REN, SETDB1 | KIF11 2009/4885KCNH2 3525/4885CA4 744/4885 |
| US-20090203135-A1 | Glycoconjugates of RNA Interference Agents | RNASE1, B3GAT3, UGCG | KIF11 2760/4885KCNH2 4807/4885CA4 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.